Track the Indivior PLC stock price and the full insider trade history of the company, a listed issuer based in United Kingdom. Shares trade on the UK market, under the authority of RNS (LSE). Market capitalisation: €4.8bn. The latest transaction was filed on 7 January 2026 (Acquisition). Among the most active insiders: Mark Crossley. Every trade is accessible without an account.
85
Insider Decl.
n/a
Thresholds
€3m
36 ops.
Buy Volume
€16m
12 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Indivior PLC Strong Buy (bullish), based on 6 analysts. Average price target: US$50.83.
52Σ signal
Buys €3m€16m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,479 of 28,892 companies
60.1
score / 100
Value
41
Quality
79
FCF yld-2.0%
Earn yld4.4%
EV/EBITDA16.9x
ROE·
Gross mgn80%
Net mgn17%
Debt/EBITDA1.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
2,764 sharesOutside a trading venueISINISIN GB00BN4HT335RNS:5560513-0
25 of 85 declarations
About Indivior PLC
Indivior PLC is a pharmaceutical company focused on the treatment of substance use disorders. It is listed on the London Stock Exchange under the ticker INDV.